Rezetamig Human Monoclonal Antibody
Rezetamigis a research-grade recombinant antibody targeting CD22. Produced in mammalian cells with native-like glycosylation. Highlights Research Grade: For PK/PD studies, assay development, and ADA research. Native Glycosylation: Mammalian expression ensures native-like patterns.
Product Specifications
Product Name Alternative
Sialic acid-binding Ig-like lectin 2, Siglec-2, CD22, T-cell surface antigen Leu-14, BL-CAM, SIGLEC2, B-lymphocyte cell adhesion molecule, B-cell receptor CD22, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain
UniProt
P07766, P20273
Reactivity
Human
Clonality
Monoclonal
Conjugation
Unconjugated
Purification
Protein A/G purified from cell culture supernatant.
Concentration
Lot dependent
Purity
>95% purity as determined by SDS-PAGE.
Form
Liquid
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Tested Applications
ELISA, FA, FACS, In vivo
Host or Source
Human
Preservative
0.01M PBS, pH 7.4.
Isotype
Immunoglobulin half G4-kappa_G4 (VH-h-CH2-CH3)
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
